Retigabine
Epilepsy in Children
Xenon Pharmaceuticals Inc.Small moleculePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 39/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Epilepsy in Children cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MELATONIN National Taiwan University Hospital | Phase 2/3 | B |
Sulthiame University Hospital, Angers | D | |
Fycompa Eisai Inc. | Phase 2 | NR |
Mgcnd00Ep1 MGC Pharmaceuticals d.o.o | Phase 2 | NR |
Same molecule, other indications
Retigabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →